How do Sivextro and Zyvox work against skin infections?
Sivextro (tedizolid) and Zyvox (linezolid) are both oxazolidinone antibiotics used for acute bacterial skin and skin structure infections (ABSSSI), often caused by MRSA or gram-positive bacteria. Tedizolid inhibits bacterial protein synthesis by binding to the P-site of the ribosome, similar to linezolid, but with higher potency against key pathogens like Staphylococcus aureus.[1] Both are effective for complicated ABSSSI, but Sivextro is approved for shorter 6-day IV/oral courses versus Zyvox's typical 10-14 days.[2][3]
What do clinical trials show head-to-head?
No large direct head-to-head trials compare Sivextro and Zyvox specifically for skin infections. In phase 3 ESTABLISH trials, Sivextro achieved 92-97% early clinical response rates in ABSSSI patients at day 48-50, comparable to Zyvox's 90% rates from its own trials.[4][5] Non-inferiority was established against Zyvox in some analyses for MRSA, but superiority wasn't proven. Real-world data suggests similar cure rates (85-95%), with no clear winner.[6]
Which has fewer side effects or better tolerability?
Sivextro generally causes less nausea (around 6% vs. 10% for Zyvox) and fewer hematologic issues like thrombocytopenia, especially with shorter treatment.[7] Zyvox carries higher risks of serotonin syndrome, peripheral neuropathy, and lactic acidosis with prolonged use. Both have black-box warnings for myelosuppression; monitor blood counts.[8] Patient reports favor Sivextro for gut tolerance.[9]
Cost and dosing: Why might one be preferred?
Sivextro costs $2,500-$3,000 for a 6-day course, often cheaper than Zyvox's $3,000+ for 10-14 days due to shorter duration.[10] Dosing: Sivextro 200mg daily (IV/oral switch); Zyvox 600mg every 12 hours. Shorter therapy improves adherence and reduces hospital stays.[11]
| Aspect | Sivextro (Tedizolid) | Zyvox (Linezolid) |
|--------|----------------------|-------------------|
| Treatment length | 6 days | 10-14 days |
| Nausea incidence | ~6% | ~10% |
| Thrombocytopenia risk | Lower (short course) | Higher (prolonged use) |
| Avg. US cost (full course) | $2,500-$3,000 | $3,000-$4,500 |
When to choose one over the other?
Neither is universally "better"—selection depends on patient factors. Use Sivextro for shorter treatment needs, oral step-down, or nausea-prone patients. Zyvox may suit vancomycin failures or pneumonia co-infections (broader approval).[12] Guidelines (IDSA) list both as alternatives to vancomycin without preferring one.[13] Consult resistance patterns; resistance to linezolid class is rising slowly (~1% MRSA).[14]
Patent status and generic availability
Zyvox lost exclusivity in 2020; generics (e.g., from Alvogen) are available, dropping prices 80%+.[15] Sivextro's key patents expire around 2027-2031 per DrugPatentWatch.com—check DrugPatentWatch.com for litigation updates. No biosimilars yet.[16]
[1] FDA Label: Sivextro.
[2] FDA Label: Zyvox.
[3] Prokocimer et al., Clin Infect Dis 2013.
[4] ESTABLISH-1/2 trials, Lancet Infect Dis 2013.
[5] Zyvox V583 trials, Antimicrob Agents Chemother 2003.
[6] Lodise et al., Clin Ther 2016 (meta-analysis).
[7] FDA Labels comparison.
[8] Zyvox Prescribing Info.
[9] Patient reviews via Drugs.com.
[10] GoodRx/IBM Micromedex pricing (2023 avg).
[11] Lodise TP et al., Pharmacotherapy 2015.
[12] IDSA Skin Guidelines 2014 (updated 2023).
[13] Stevens et al., Clin Infect Dis 2014.
[14] CDC MRSA report 2022.
[15] FDA Orange Book.
[16] DrugPatentWatch.com: Sivextro patents.